Acrux Limited · ASX:ACR
Acrux — Shareholder Meeting (November 2018)
20 slides from Acrux's shareholder meeting presentation, Nov 1, 2018
Slide 1: Acrux AGM Presentation
For personal use only ACRUX AGM PRESENTATION (ASX: ACR) November 2018
Slide 2: Introduction: Ross Dobinson, Non-Executive Chairman
For personal use only INTRODUCTION: ROSS DOBINSON NON-EXECUTIVE CHAIRMAN 2
Slide 3: Operational Review: Michael Kotsanis, CEO & Managing Director
For personal use only OPERATIONAL REVIEW: MICHAEL KOTSANIS CEO & MANAGING DIRECTOR 3
Slide 4: Forward Looking Statements
FORWARD LOOKING STATEMENTS For personal use only This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Acrux to be mate
Slide 5: Strong Operational and Commercial Progress
STRONG OPERATIONAL AND COMMERCIAL PROGRESS For personal use only Deliberate expansion & On-target regulatory Continued excellence in optimisation of portfolio submissions research & development • Successfully expanded generic topical • Demonstrated successful execution of • Significant progression a
Slide 6: Increasing Investor Engagement
INCREASING INVESTOR ENGAGEMENT For personal use only Key recent catalysts: Share price performance (last 12 months) 02 August: Acrux has Paragraph IV generic of Jublia® Share Price (A$) accepted for review by FDA 0.3 Key recent catalysts: 0.25 17 October: Acrux has generic 0.2 testosterone solution
Slide 7: Our Approach
OUR APPROACH For personal use only Market screening to identify high potential prescription 165 identified molecules, IDENTIFY topical products each with >US$10m in sales Acrux is developing a diversified portfolio of topically applied R&D team with highly specific topical expertise drive 13 molecul
Slide 8: Multiple Advantages for Generic Prescription Product Development
MULTIPLE ADVANTAGES FOR GENERIC PRESCRIPTION PRODUCT DEVELOPMENT For personal use only Traditional development Acrux’s generic development portfolio Market size A new drug may have a significant market Attractive market and licensee terms opportunity, however… Speed …it takes ~10 years1 to develop a
Slide 9: Acrux Is Making Excellent Progress Across Its Generic Topical Portfolio
ACRUX IS MAKING EXCELLENT PROGRESS ACROSS ITS GENERIC TOPICAL PORTFOLIO For personal use only In FY19, Acrux intends to: Overview of Acrux’s current generic topical portfolio of 13 assets ✓ Submit 1 additional Formulation Process Bioequiv. / Regulatory Approved / Development Development clinical2 Su
Slide 10: Acrux Pipeline Represents a Large Market with Relatively Low Competition
ACRUX PIPELINE REPRESENTS A LARGE MARKET WITH RELATIVELY LOW COMPETITION For personal use only Addressable market value1 ($USm) # of commercialised generic (ANDA) Addressable market competitors on the market 1,429 5+ Generics 139 41 +US$1.4 bn 4 Generics Based on 13 products currently in the Acrux 3
Slide 11: Each Drug Will Follow the Same Commercialisation Pathway
EACH DRUG IN ACRUX’S GENERIC TOPICAL PORTFOLIO WILL FOLLOW THE SAME COMMERCIALISATION PATHWAY For personal use only An illustrative pathway for a successfully launched asset: Submit dossier to Secure licensing Generate ongoing Launch product FDA for filing agreement revenue stream ▪ Submit dossier f
Slide 12: First Generic Topical Product to Reach FDA Review
FIRST GENERIC TOPICAL PRODUCT TO REACH ‘FDA REVIEW’ For personal use only Jublia® (efinaconazole) Topical Solution, 10% is a prescription antifungal What is Jublia®? medicine used to treat fungal infections of the toenails (Onychomycosis), which effects 10% of the population1 Submit dossier Licensin
Slide 13: Acrux Is Operating in an Attractive US$18bn Market
ACRUX IS OPERATING IN AN ATTRACTIVE US$18bn MARKET For personal use only >US$400bn1 ~US$18bn2 Topical generics represent an attractive and significant market opportunity 12% Other 4% Topical ✓ US$18bn market opportunity 47% Generic ✓ Currently, generics make up only 47% of the topical market, this i
Slide 14: Experienced Management Team with a Proven History
EXPERIENCED MANAGEMENT TEAM WITH A PROVEN HISTORY OF MEETING OPERATIONAL MILESTONES For personal use only Management team World class topical R&D team Michael Kotsanis BSc, MBus “I am extremely proud to lead an expert CEO & Managing Director topical drug development team. Our in- Experienced leader
Slide 15: Strategic Direction Led by a Board with Highly Relevant Expertise
STRATEGIC DIRECTION LED BY A BOARD WITH HIGHLY RELEVANT EXPERTISE For personal use only Michael Kotsanis Ross Dobinson CEO & Managing Director Non-Executive • Experienced leader in the pharmaceuticals industry with Chairman demonstrated success commercialising generic products Capital markets expert
Slide 16: Multiple Upcoming Value Catalysts
MULTIPLE UPCOMING VALUE CATALYSTS For personal use only Acrux objectives FY19 Scale up 6 projects Submit 2 Add further from Acrux additional products to laboratory to dossiers to FDA generic portfolio CMOs CY19 Acrux expects to generate First generic first revenues from its revenues generic portfoli
Slide 17: Financial Review: Tim Bateman, CFO
For personal use only FINANCIAL REVIEW: TIM BATEMAN CFO 17
Slide 18: Full Year Profit and Loss
FULL YEAR PROFIT AND LOSS Full Year Ending 2018 2017 For personal use only $'000 $'000 % Royalty revenue 2,687 23,321 (88.5%) Interest & other Income 745 613 21.5% Total revenue and other income 3,432 23,934 (85.7%) R&D investment (10,624) (9,247) 14.9% Other operating costs (2,705) (2,198) 23.1% No
Slide 19: Full Year Cashflow
FULL YEAR CASHFLOW Full Year Ending 2018 2017 For personal use only $'000 $'000 % Cash flow from operating activities Receipts from product agreements 7,872 21,822 (63.9%) Payments to suppliers and employees (12,731) (10,748) 18.4% Interest received 610 637 (4.2%) Income tax paid (1,033) (6,335) (83
Slide 20: Thank You
For personal use only THANK YOU Investor enquiries Michael Kotsanis Anthony England Acrux Limited Vesparum Capital CEO & Managing Director Director P: + 61 3 8379 0100 P: + 61 3 8582 4800 E: michael.kotsanis@acrux.com.au E: Acrux@vesparum.com Visit our website: http://www.acrux.com.au/ Follow us on